AI-generated analysis. Always verify with the original filing.
Sunshine Biopharma, Inc. entered into an engagement agreement with Aegis Capital Corp. on March 6, 2026. The agreement is filed as Exhibit 99.1 with the 8-K filing dated March 9, 2026.
Event Type
Disclosure
Voluntary
Variant
8-K
Other Events. On March 6, 2026, Sunshine Biopharma Inc. (the “Company”) entered into an engagement agreement with Aegis Capital Corp. (“Aegis”) pursuant to whic
Financial Statements and Exhibits. Exhibit No . Description 99.1 Engagement Agreement between the Company and Aegis 104 Cover Page Interactive Data File (embedd